Aurobindo Pharma Limited
https://www.aurobindo.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aurobindo Pharma Limited
Aurobindo Reprimanded By SEBI Over US FDA Warning Disclosure
The Securities and Exchange Board of India has warned Aurobindo that it did not disclose sufficient information about a US FDA warning letter that it received in connection with its Unit 1 API facility in Hyderabad early this year.
Can The Pipeline Soothe A US Generics Pricing Headache?
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.
Can The Pipeline Soothe A US Generics Pricing Headache?
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.
Aurobindo Matches Lupin With Teva Austedo Settlement
Aurobindo has settled US patent litigation with Teva over Austedo, giving the Indian company an April 2033 launch date for generic deutetrabenazine, matching the date gained by Lupin in an earlier settlement.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Acrotech Biopharma, LLC
- APL
- Glaxo (India)
- TL Biopharmaceutical AG.